Viking Therapeutics (VKTX) leads the race to win FDA Rx-to-OTC switch for an oral weight loss drug belonging to GLP-1 class ...

The results of Novo Nordisk’s phase 1 trials shows the oral weight loss pill could be more effective than semaglutide.

BioAge Labs, a biopharmaceutical startup focused on obesity drugs, is looking to raise nearly $200 million in its recently ...

The arrival of GLP-1 analogue drugs (such as Wegovy) marked a huge shift in the weight loss drug market. These drugs have ...

Terns Pharma is in the process of developing TERN-601 for the treatment of patients with obesity. See why I rate TERN stock ...

Sometimes diet and exercise are not enough to help the 100 million Americans with obesity lose weight and prevent health ...

Discover an untold biotech story and find out how Pfizer missed an opportunity in the GLP-1 market because of an exit in the ...

An experimental weight loss pill developed by biotechnology company Terns Pharmaceuticals helped some people with obesity lose more than 5% of their body weight in a small Phase 1 trial, supporting ...

Novo Nordisk said on Wednesday that its highly anticipated experimental weight-loss pill amycretin was safe and tolerable for patients in an early ... data from an early study on a subcutaneous ...

Weight loss injections have become increasingly popular among adults and they’ve been proven to work. Now, there’s evidence that those drugs could be used to treat obesity in kids, as well.

Shares of Novo Nordisk NVO lost 5.5% on Friday after the company announced top-line data from a mid-stage study evaluating ...

In a phase 1 trial, Novo Nordisk's experimental obesity drug amycretin led to up to 13% weight loss in just three months.